Enterosys welcomes its new CEO

CEO Jean-Christophe Malrieu

With its unique combination of scientific expertise, R&D skills and state-of-the-art technologies, Enterosys is set to become a leading preclinical contract research organization (CRO) in the market.

Enterosys has a technological lead in the investigation of the digestive sphere. The objective of the company is to become the reference player in the field of the gut, the gut-brain axis and the gut-organ axis.

With such a line of investigation, Enterosys aims to become a key research partner in the field on neurodegenerative, metabolic and intestinal diseases.

Jean-Christophe Malrieu is an entrepreneur with a Master’s degree in Business Management from the University of Paris Dauphine and a Bachelor’s degree in Economics. Before joining SME companies as CEO, he had a long international experience in multinational companies such as Unilever (18 years) and Shiseido (4 years). 

Jean-Christophe has extensive experience in innovation and development, marketing and sales, finance, export, the food and beauty industry, and the healthcare sector for 12 years.  In 2010, he became president and CEO of Phythea, a French nutraceutical leader specializing in joint health and women’s health. In early 2017, he co-founded A-Mansia Biotech SA in Belgium, a spin-off from Wageningen University and UC Leuven aiming to fight obesity and type 2 diabetes with Akkermansia muciniphila, a key bacterium species of the human gut microbiota discovered in 2006 by the company’s founders. In 2018,  Jean-Christophe raised €25 million to fund the development of A-Mansia, including €18 million in a Series A round. In December 2021, he decided to join ENTEROSYS as CEO.




Salon BioFIT 2023

Join us for Salon BioFIT2023 where we'll come together to foster a sens of community, collaboration and success. Let's meet !Booking plateform link Maybe you can also like : Foodtech innovative research boosted with gut and gut-brain axis

Enteric neurons for functional applications in health care

Pharmaceuticals Studying the role of the Enteric Nervous System (ENS) in the development of gut-brain pathologies (e.g., Alzheimer’s, Parkinson’s, diabetes, aging, stress, visceral pain) is an ever-expanding research topic. Researchers are starting to propose numerous...

Enteric neurons and glycemia control

The gut-brain axis:You have a message from your gut In the intestine, gut distension and nutrients are detected by mechanoreceptors and chemoreceptors, respectively. The activation of these receptors sends an afferent nervous message to the hypothalamus in the brain....

The enteric nervous system is our second brain

  The enteric nervous system (ENS), referred to as the “second brain,” is an extensive network of different cell types located along the digestive tract. It consists in enteric neurons, enteric glial cells and interstitial cells of Cajal. This network of cells is...